老年群体纳入新药评估的现状:差距与实施需求
该文指出,老年人在其获批后可能使用的药物临床试验中持续存在代表不足的问题。近期要求临床试验参与者代表患者人群的立法带来希望,但仍需按年龄、性别、种族及老年共病收集疾病患病率数据以评估代表性,并需就老年患者相关定义和数据收集达成共识。还需扩大老年研究队伍、研究设施及社区参与。
要点
- 老年人在新药临床试验中代表不足的问题持续存在。
- 需按年龄、性别、种族及老年共病收集患病率数据以评估代表性。
- 需就衰弱、认知与躯体功能等老年相关定义和数据收集达成共识。
核心结论
- 尽管近期立法要求临床试验参与者代表患者人群,老年人仍在新药试验中代表不足,需采取多项实施措施填补差距。
研究设计与样本
- 本文为发表于 J Am Geriatr Soc 的论述性文章,未报告系统检索范围或样本量。
主要发现
- 老年人在其可能使用的药物临床试验中持续代表不足。
- 需收集按年龄、性别、种族细分的疾病患病率及老年共病数据以评估试验参与者代表性。
- 需就老年患者人群相关定义和数据收集达成共识,以评估共病、衰弱、认知与躯体功能的影响。
- 需扩大老年研究队伍、学术中心与社区及长期照护机构的研究设施,并促进传统代表不足社区的参与。
临床怎么用
- 在评估新药试验代表性时,应关注按年龄、性别、种族及老年共病细分的患病率数据。
- 推动就衰弱、认知与躯体功能等老年相关定义和数据收集达成共识。
- 加强老年研究队伍建设及社区和长期照护机构的研究能力,促进代表不足社区参与临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Under-representation of subgroups of the population in clinical trials has been and continues to be a problem despite goals of academia, industry, and government. Older adults are among the groups that are under-represented in trials of medications that they are likely to receive once marketing approval has been received. Recent legislation that mandates that clinical trial participants be representative of patient population has been passed and creates hope that greater numbers of older adults will be enrolled in clinical trials and that they will be representative of "typical" geriatric patients. However, there is the need for collection of current data on disease prevalences with granularity as to age, gender, and race as well as geriatric co-morbidities to assess the representativeness of clinical trial participants relative to patient populations. Consensus on definitions and collection of data relevant to geriatric patient populations are needed to evaluate effects of comorbidities, frailty, cognitive and physical function. There will also be a need for expansion of the geriatric research workforce, facilities for research both in academic centers but also in the community and long-term care facilities, and for engagement with and involvement of communities that have been traditionally under-represented to conduct clinical trials that enroll truly representative patient populations.
引用
- Schwartz JB. Current status of inclusion of older groups in evaluations of new medications: Gaps and implementation needs to fill them. J Am Geriatr Soc. 2024. PMID: 38600697. doi:10.1111/jgs.18912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。